Medicine Stock Based on Genetic Algorithms: Returns up to 27.16% in 7 Days
Medicine Stock
The Medicine Stocks Package is designed for investors and analysts who need predictions for the best stocks to buy in the Medicine Industry. It includes 20 stocks with bullish and bearish signals and indicates the best medicine stocks to trade:
- Top 10 Medicine stocks for the long position
- Top 10 Medicine stocks for the short position
Package Name: Medicine Stocks
Recommended Positions: Short
Forecast Length: 7 Days (08/04/2017 – 08/11/2017)
I Know First Average: 10.93%
8 out of 10 top stock picks from the algorithm decreased as predicted for this short-term forecasting period. TEVA saw monumental growth of 27.16% in just 7 Days. ENDP, and INSM also had excellent performances with returns of 23.41% and 17.43% respectively. <![CDATA[The package had an overall average return of 10.93%, providing investors with a premium of 12.18% over the S&P 500’s return of -1.25% during the same period.
Teva Pharmaceutical Industries Limited (TEVA) develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The companys Generic Medicines segment offers generic medicines, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The companys Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the womens health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinsons disease; Nuvigil for the treatment of excessive sleepiness associated with narcolepsy and certain other disorders; Fentora/Effentora for the treatment of breakthrough pain in opioid-tolerant adult patients with cancer; and Zecuity, a prescription transdermal system for the acute treatment of migraine with or without aura in adults. This segments products in the respiratory market include ProAir, ProAir Respiclick, QVAR, and Duoresp Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda, Granix, Trisenox, Synribo, Lonquex, Myocet, Eporatio, Tevagrastim/Ratiograstim, and Trisenox products in the oncology market. This segment also offers a portfolio of products in the womens health category, which includes ParaGard, Plan B One-Step, OTC/Rx, Zoely, Seasonique, and Ovaleap, as well as other products. Teva Pharmaceutical Industries Limited (TEVA) has collaboration arrangements with Takeda Pharmaceutical Company Limited, Procter & Gamble Company, Intel, and Regeneron Pharmaceuticals, Inc. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.
Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.
How to interpret this diagram
Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.